Chronic liver damage leads to scarring (fibrosis) of the liver tissue, which can ultimately lead to increased blood pressure in the vascular system of the gastrointestinal tract (i.e. portal hypertension).
Portal hypertension can result in serious complications.
In a study from MedUni Vienna, scientists found that the increasing severity of portal hypertension is paralleled by inflammatory reactions in the body (systemic inflammation).
They found that common high blood pressure drug beta-blockers have anti-inflammatory effects in advanced liver disease.
For many years, beta-blockers have been used as standard drug treatment, but only 50% to 60% of patients achieve a clinically relevant reduction in portal vein pressure.
The new study shows for the first time that beta-blockers also have an impact on systemic inflammation.
In this study, the researchers found biomarkers of systemic inflammation prior to and subsequently during treatment with beta-blockers.
They showed that patients suffering from advanced stages of cirrhosis were not only more likely to have a systemic inflammatory response but were also more likely to benefit from the anti-inflammatory effects of beta-blockers.
The cirrhotic patients achieved a reduction in inflammatory markers (such as the white blood cell count) under beta-blocker therapy, and they had much fewer complications of portal hypertension and lower death risk.
The team says after further validation in clinical trials, these findings may help to predict the benefit of beta-blocker treatment more accurately and thus give patients optimal advice.
If you care about blood pressure, please read studies about how the COVID-19 pandemic harms blood pressure health, and this daily snack may help you reduce high blood pressure.
For more information about blood pressure, please see recent studies that, sometimes, the best treatment for high blood pressure is to wait, and results showing blood pressure rising at night may double the death risk in people with diabetes.
The study was published in Gut and conducted Thomas Reiberger.
Copyright © 2022 Knowridge Science Report. All rights reserved.
